Model calibration in the continual reassessment method
- 15 June 2009
- journal article
- other
- Published by SAGE Publications in Clinical Trials
- Vol. 6 (3), 227-238
- https://doi.org/10.1177/1740774509105076
Abstract
Background The continual reassessment method (CRM) is an adaptive model-based design used to estimate the maximum tolerated dose in dose finding clinical trials. A way to evaluate the sensitivity of a given CRM model including the functional form of the dose-toxicity curve, the prior distribution on the model parameter, and the initial guesses of toxicity probability at each dose is using indifference intervals. While the indifference interval technique provides a succinct summary of model sensitivity, there are infinitely many possible ways to specify the initial guesses of toxicity probability. In practice, these are generally specified by trial and error through extensive simulations. Methods By using indifference intervals, the initial guesses used in the CRM can be selected by specifying a range of acceptable toxicity probabilities in addition to the target probability of toxicity. An algorithm is proposed for obtaining the indifference interval that maximizes the average percentage of correct selection across a set of scenarios of true probabilities of toxicity and providing a systematic approach for selecting initial guesses in a much less time-consuming manner than the trial-and-error method. The methods are compared in the context of two real CRM trials. Results For both trials, the initial guesses selected by the proposed algorithm had similar operating characteristics as measured by percentage of correct selection, average absolute difference between the true probability of the dose selected and the target probability of toxicity, percentage treated at each dose and overall percentage of toxicity compared to the initial guesses used during the conduct of the trials which were obtained by trial and error through a time-consuming calibration process. The average percentage of correct selection for the scenarios considered were 61.5 and 62.0% in the lymphoma trial, and 62.9 and 64.0% in the stroke trial for the trial-and-error method versus the proposed approach. Limitations We only present detailed results for the empiric dose toxicity curve, although the proposed methods are applicable for other dose—toxicity models such as the logistic. Conclusions The proposed method provides a fast and systematic approach for selecting initial guesses of probabilities of toxicity used in the CRM that are competitive to those obtained by trial and error through a time-consuming process, thus, simplifying the model calibration process for the CRM.Keywords
This publication has 9 references indexed in Scilit:
- The Neuroprotection with Statin Therapy for Acute Recovery Trial (Neustart): An Adaptive Design Phase I Dose-Escalation Study of High-Dose Lovastatin in Acute Ischemic StrokeInternational Journal of Stroke, 2008
- Coherence principles in dose-finding studiesBiometrika, 2005
- Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.Blood, 2005
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment MethodBiometrics, 2002
- Sequential Designs for Phase I Clinical Trials with Late‐Onset ToxicitiesBiometrics, 2000
- Continual Reassessment Method: A Likelihood ApproachBiometrics, 1996
- Consistency of continual reassessment method under model misspecificationBiometrika, 1996
- The continual reassessment method in cancer phase i clinical trials: A simulation studyStatistics in Medicine, 1993
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in CancerBiometrics, 1990